Reclast and Orthodonture: Safety and Precautions
Patients on Reclast (zoledronic acid) can undergo orthodontic treatment, but comprehensive dental evaluation and preventive care must be completed before starting Reclast, and invasive dental procedures should be avoided during treatment due to the risk of osteonecrosis of the jaw (ONJ).
Key Safety Concern: Osteonecrosis of the Jaw (ONJ)
The primary concern with Reclast during orthodontic treatment is ONJ, a serious complication where exposed jaw bone fails to heal. The FDA-approved labeling for Reclast explicitly states that patients should have a dental examination before starting treatment and avoid invasive dental procedures whenever possible 1.
Risk Profile for ONJ
- ONJ risk increases with frequency, dose, and duration of bisphosphonate administration 2
- With adjuvant dosing regimens (less frequent than cancer treatment), ONJ incidence ranges from 0.8% to 2.1% in clinical trials 2
- This is substantially lower than the risk seen with monthly high-dose regimens used for bone metastases
- Risk factors include tooth extractions, invasive dental procedures, poor oral hygiene, and diabetes 3
Pre-Treatment Dental Protocol
Before initiating Reclast, the following must occur 2:
- Comprehensive dental evaluation of both hard and soft tissues
- Complete any needed invasive dental procedures before starting Reclast
- Allow adequate healing time (ideally 14-21 days) after dental procedures before first infusion 4
- Treat active oral infections and eliminate high-risk sites
During Orthodontic Treatment on Reclast
What IS Safe:
- Routine orthodontic appliance placement and adjustments (brackets, wires, elastics)
- Non-invasive orthodontic procedures
- Excellent oral hygiene maintenance (brushing, flossing, fluoride rinses) 4, 1
- Regular monitoring by both orthodontist and prescribing physician
What to AVOID:
- Tooth extractions (the most common trigger for ONJ) 2
- Dental implant placement
- Invasive periodontal surgery
- Any procedure involving manipulation of jaw bone
If Invasive Dental Work Becomes Necessary
There is conflicting evidence on whether to withhold Reclast before invasive procedures 2:
- One approach: Stop Reclast 2 months before oral surgery and delay restarting until osseous healing occurs
- Alternative view: A short break has no effect since bisphosphonates remain in bone for years after stopping
- Practical recommendation: Given Reclast's annual dosing schedule, if invasive dental work is needed, time it to occur as far as possible from the last infusion (ideally 6+ months after) and delay the next dose until healing is complete
Additional Monitoring Requirements
Beyond dental concerns, patients on Reclast require 2:
- Serum calcium measurement before each dose (hypocalcemia is a contraindication)
- Renal function monitoring (creatinine clearance must be ≥35 mL/min)
- Adequate calcium (1500 mg daily) and vitamin D (800 IU daily) supplementation 1
- Hydration with at least 2 glasses of fluid before infusion 1
Research Evidence on Orthodontic Movement
Animal studies show that zoledronic acid significantly inhibits orthodontic tooth movement 5. One study found a 99.6% reduction in tooth movement compared to controls, along with decreased osteoclasts and inflammatory cells in the periodontal ligament. However, another study using lower doses found no significant decrease in tooth movement but significant inhibition of bone and root resorption 6.
Clinical implication: While orthodontic treatment can proceed, tooth movement may be slower or less predictable. The orthodontist should be informed of Reclast use to adjust treatment planning accordingly.
Critical Patient Education Points
- Inform their orthodontist/dentist about Reclast treatment
- Maintain excellent oral hygiene throughout treatment
- Report any jaw pain, swelling, or exposed bone immediately
- Understand that if ONJ develops, they need referral to a specialist (oral maxillofacial surgeon with ONJ expertise)
Common Pitfall to Avoid
Do not assume that because Reclast is given only once yearly, the ONJ risk is negligible. Cases of ONJ have been documented even with the once-yearly osteoporosis dosing regimen 7, 3. The drug's effects on bone persist long after administration, maintaining both therapeutic benefits and risks.